ProCE Banner Activity

Experts Answer Questions on Integrating CAR T-Cell Therapy Into the Management of DLBCL, FL, MCL, and CLL/SLL to Improve Outcomes

Clinical Thought

In this commentary, Michael R. Bishop, MD; Julie M. Vose, MD, MBA; and Kathleen Dorritie, MD, address some of the most pressing questions on integrating CAR T-cell therapy into the management of DLBCL, FL, MCL, and CLL/SLL to improve patient outcomes.

Released: June 27, 2023

Share

Faculty

Michael R. Bishop

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Kathleen Dorritie

Kathleen Dorritie, MD

Assistant Professor of Medicine
Division of Hematology Oncology
UPMC, University of Pittsburgh
Pittsburgh, Pennsylvania

Julie M Vose

Julie M Vose, MD, MBA

Payne Presidential Chair
Chief, Division of Hematology/Oncology
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This program is intended for hematologists/oncologists and other multidisciplinary care team members who treat patients with lymphomas.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, and competence in integrating the latest clinical guidance and expert recommendations in the application of CAR T-cell therapy for the treatment of lymphomas into clinal practice.

Disclosure

Program Director

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Michael R. Bishop, MD: consultant/advisor/speaker: CRISPR Therapeutics, Kite/Gilead, Novartis; researcher: Autolus.

Primary Author

Kathleen Dorritie, MD

Assistant Professor of Medicine
Division of Hematology Oncology
UPMC, University of Pittsburgh
Pittsburgh, Pennsylvania

Kathleen Dorritie, MD: consultant/advisor/speaker: Bristol Myers Squibb; researcher (paid to institution): Genmab, Juno/Bristol Myers Squibb, Kite/Gilead, Janssen.

Julie M Vose, MD, MBA

Payne Presidential Chair
Chief, Division of Hematology/Oncology
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, MEI Pharma; researcher: Epizyme, Kite, Loxo, Novartis.